Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.

Cancer Treat RevJul 27, 2026 (epub)
Clinical ResearchOncology (Medical)

Lianne M Haveman, Lisa L Hjalgrim, Cristina Mata Fernández et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the feasibility of maintenance therapy for Ewing sarcoma (ES) using vinorelbine and low-dose cyclophosphamide. The review included 20 studies on ES and other pediatric sarcomas, highlighting modest clinical activity in heavily pretreated patients. The strongest evidence came from rhabdomyosarcoma, where maintenance therapy improved long-term survival.

Key findings

  • 20 studies were included, with 11 focusing on Ewing sarcoma patients.
  • Vinorelbine and low-dose cyclophosphamide showed modest clinical activity in relapsed or refractory Ewing sarcoma.
  • The EpSSG RMS 2005-trial demonstrated improved long-term survival with vinorelbine/cyclophosphamide maintenance in rhabdomyosarcoma.

Why it matters

Understanding the potential role of maintenance therapy in Ewing sarcoma could help improve outcomes in a patient population with high relapse rates. This review provides a rationale for further investigation into effective maintenance strategies.

Source

Published in Cancer Treat Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.